Results 71 to 80 of about 137,733 (396)

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard   +5 more
wiley   +1 more source

Fournier's gangrene in a patient on dapagliflozin treatment for type 2 diabetes

open access: yesJournal of Diabetes, 2019
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are novel agents in the treatment of type 2 diabetes (T2D) that act by inhibiting glucose reabsorption in the proximal renal tubule.
C. E. Onder   +4 more
semanticscholar   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

open access: yesMolecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson   +2 more
wiley   +1 more source

Dicumarol [PDF]

open access: yes, 1945
Thesis (M.D.)--Boston ...
Steel, Robert MacDonald
core  

Fournier's Gangrene: 10-Year Experience of a Plastic Surgery and Burns Department at a Tertiary Hospital.

open access: yesActa Médica Portuguesa, 2019
INTRODUCTION Fournier gangrene is a polymicrobial life threatening infection of perineal subcutaneous soft tissues with its point of origin in urologic, colorectal or skin diseases. Although more frequent in elderly and men, it can affect all genders and
J. Louro   +6 more
semanticscholar   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Fierce Fusarium solani infection in diabetic foot – A double-barrel rifle

open access: yesJournal of Current Research in Scientific Medicine
Diabetic foot is one of the most serious and prevalent manifestations of diabetes mellitus. In a study conducted in Eastern India, 31.7% of diabetic patients with infections in the lower limb had positive fungal cultures.
Subha Kanthiah   +3 more
doaj   +1 more source

Malrotation with Distal Duodenal Necrosis in a Neonate

open access: yesIranian Journal of Pediatric Surgery, 2020
Malrotation with midgut volvulus often results in gangrene of midgut with relative sparing of duodenum. An extremely unusual case of Malrotation with isolated necrosis of distal duodenum is described with brief review of literature.
Vinit kumar Thakur   +5 more
doaj   +1 more source

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

open access: yesMolecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués   +3 more
wiley   +1 more source

Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report

open access: yeseJHaem, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. It is associated with poor prognosis and heterogenous presentation. The CD123‐directed cytotoxin, Tagraxofusp, is a targeted therapy for BPDCN. Here, we
Jad Sibai   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy